Soleus Capital Management’s BioAtla BCAB Stock Holding History

Soleus Capital Management’s Portfolio BCAB Stock Details BCAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-50,350	Closed	-$4.43M	–	86
2024 Q3	$4.43M	Sell	50,350 -27,676	-35%	-$2.32M	0.34%	63
2024 Q2	$5.34M	Sell	78,026 -3,278	-4%	-$390K	0.47%	60
2024 Q1	$14M	Hold	81,304	–	–	1.04%	30
2023 Q4	$10M	Sell	81,304 -5,820	-7%	-$505K	1.11%	29
2023 Q3	$7.41M	Buy	87,124 +700	+0.8%	+$89.2K	0.68%	40
2023 Q2	$13M	Hold	86,424	–	–	1.44%	19
2023 Q1	$11.6M	Buy	86,424 +2,016	+2%	+$363K	1.2%	24
2022 Q4	$34.8M	Buy	84,408 +16,398	+24%	+$6.8M	5%	4
2022 Q3	$26.2M	Buy	68,010 +2,756	+4%	+$902K	3.56%	7
2022 Q2	$9.3M	Buy	65,254 +14,946	+30%	+$2.38M	1.45%	25
2022 Q1	$12.6M	Hold	50,308	–	–	1.62%	23
2021 Q4	$49.4M	Hold	50,308	–	–	4.94%	5
2021 Q3	$74.1M	Sell	50,308 -5,577	-10%	-$10.9M	11.54%	1
2021 Q2	$118M	Sell	55,885 -7,702	-12%	-$17.4M	18.21%	1
2021 Q1	$162M	Hold	63,587	–	–	29.12%	1
2020 Q4	$108M	Buy	+63,587	New	+$106M	14.27%	2

Other funds holding BCAB

AFM

Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

HCM

Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Soleus Capital Management's BCAB Position: Q4 2024 in Review

Soleus Capital Management sold out of BioAtla (BCAB) in Q4 2024, closing a stake of 50,350 shares — an estimated $4.43M sold.

Soleus Capital Management first reported a position in BCAB in Q4 2020 and held it in 16 quarters. The position peaked at $162M in Q1 2021. 67 funds tracked by Wall St. Rank hold BCAB as of Q4 2024.

Soleus Capital Management reported no remaining BioAtla position as of Q4 2024 after selling out during the quarter.
Soleus Capital Management sold 50,350 BioAtla shares in Q4 2024, an estimated $4.43M.
Soleus Capital Management first reported a position in BioAtla in Q4 2020 and held it in 16 quarters.
Soleus Capital Management's BioAtla position peaked at $162M in Q1 2021.
67 funds tracked by Wall St. Rank held BioAtla as of Q4 2024.

Based on Soleus Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.